Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

LYRICA® CR, CV Highlights (pregabalin extended-release)


These highlights do not include all the information needed to use LYRICA CR safely and effectively. See full prescribing information for LYRICA CR.

LYRICA® CR (pregabalin) extended-release tablets, for oral use, CV
Initial U.S. Approval: 2004


Warnings and Precautions, Respiratory Depression (5.4)4/2020


LYRICA CR is indicated for the management of:

  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1)
  • Postherpetic neuralgia (PHN) (1)

Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.


  • LYRICA CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. (2.1)
  • Dosing recommendations for LYRICA CR:
IndicationDosing RegimenInitial DoseMaximum Dose
DPN Pain (2.2)Single dose per day165 mg/day330 mg/day within 1 week.
PHN (2.3)Single dose per day165 mg/day330 mg/day within 1 week. Maximum dose of 660 mg/day.
  • Conversion from LYRICA Capsules or Oral Solution to LYRICA CR: See full prescribing information. (2.4)
  • Dose modification recommended in patients with renal impairment. (2.5)


Extended-release tablets: 82.5 mg, 165 mg, and 330 mg. (3)


Known hypersensitivity to pregabalin or any of its components. (4)


  • Angioedema: Angioedema [e.g., swelling of the face, mouth (tongue, lips, and gums) and neck (throat and larynx)] can occur and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue LYRICA CR immediately in patients with these symptoms. (5.1)
  • Hypersensitivity reactions: Hypersensitivity reactions (e.g., hives, dyspnea, and wheezing) can occur. Discontinue LYRICA CR immediately in these patients. (5.2)
  • Suicidal Behavior and Ideation: Antiepileptic drugs, including pregabalin, the active ingredient in LYRICA CR, increase the risk of suicidal thoughts or behavior. (5.3)
  • Respiratory Depression: May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Monitor patients and adjust dosage as appropriate. (5.4)
  • Dizziness and Somnolence: May cause dizziness and somnolence and impair patients ability to drive or operate machinery. (5.5)
  • Increased seizure frequency may occur in patients with seizure disorders if LYRICA CR is rapidly discontinued. Withdraw LYRICA CR gradually over a minimum of 1 week. (5.6)
  • Peripheral Edema: May cause peripheral edema. Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (5.7)


Most common adverse reactions reported in greater than or equal to 4% of patients treated with LYRICA CR are dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


  • Pregnancy: May cause fetal harm. Advise of potential risk to the fetus. (8.1)
  • Lactation: Breastfeeding is not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2020

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event